Results 61 to 70 of about 184,433 (313)

Identification of new genes associated with melanoma

, 2011
Purpose: Repeated failures in melanoma therapy made clear that the molecular mechanisms leading to melanoma are still poorly understood. Here, we aim to provide a more comprehensive understanding of the transcriptional profiles and signaling pathways ...
Mauerer, Andreas
core   +1 more source

Real-World Experience of Talimogene Laherparepvec (T-VEC) in Old and Oldest-Old Patients with Melanoma: A Retrospective Single Center Study

Cancer Management and Research, 2021
Johannes Kleemann, Manuel Jäger, Eva Valesky, Stefan Kippenberger, Roland Kaufmann, Markus Meissner Department of Dermatology, Venerology and Allergology, University Hospital, Goethe University, Frankfurt am Main, GermanyCorrespondence: Johannes ...
Kleemann J, Jäger M, Valesky E, Kippenberger S, Kaufmann R, Meissner M   +5 more
doaj  

Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod

Case Reports in Oncology, 2018
Simultaneous or sequential, planned administration of ipilimumab could significantly enhance the antitumor effects of nivolumab in advanced melanoma patients.
Taku Fujimura, Yumi Kambayashi, Yota Sato, Kayo Tanita, Sadanori Furudate, Akira Tsukada, Hisayuki Tono, Akira Hashimoto, Setsuya Aiba   +8 more
doaj   +1 more source

PLA1A expression as a diagnostic marker of BRAF-mutant metastasis in melanoma cancer

Scientific Reports, 2021
BRAF and NRAS are the most reported mutations associated to melanomagenesis. The lack of accurate diagnostic markers in response to therapeutic treatment in BRAF/NRAS-driven melanomagenesis is one of the main challenges in melanoma personalized therapy ...
Gang Yang, Shuya Liu, Mazaher Maghsoudloo, Marzieh Dehghan Shasaltaneh, Parham Jabbarzadeh Kaboli, Cuiwei Zhang, Youcai Deng, Hajar Heidari, Maliheh Entezari, ShaoZhi Fu, QingLian Wen, Saber Imani   +11 more
doaj   +1 more source

Safety and Tolerability of BRAF Inhibitor and BRAF Inhibitor-Based Combination Therapy in Chinese Patients With Advanced Melanoma: A Real World Study

Frontiers in Oncology, 2021
The toxicity spectrum between Chinese and Caucasian patients with melanoma who were treated with BRAF inhibitors (BRAFi) may differ. The purpose of the present study was to assess the safety and tolerability of BRAFi and BRAFi-based combination therapies
Xing Liu, Jing-jing Li, Ya Ding, Dan-dan Li, Xi-zhi Wen, De-sheng Weng, Jiu-hong Wang, Hang Jiang, Xiao-shi Zhang   +8 more
doaj   +1 more source

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

Molecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak, Iva Staniczková Zambo, Matěj Přikryl, Peter Múdry, Danica Zapletalová, Jarmila Navrátilová, Jiří Navrátil, Jan Šmarda, Liudmyla Drobot, Petr Beneš, Lucia Knopfová   +10 more
wiley   +1 more source

Evaluating cost benefits of combination therapies for advanced melanoma

, 2016
Background: Although a number of monoimmunotherapies and targeted therapies are available to treat BRAF+ advanced melanoma, response rates remain relatively low in the range of 22–53% with progression-free survival (PFS) in the range of 4.8–8.8 months ...
Ivar S Jensen, Emily Zacherle, Jie Zhang, Christopher M Blanchette, Wes Yin   +4 more
core   +1 more source

Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma

npj Precision Oncology
Modern advancements in targeted therapy and immunotherapy have significantly improved survival outcomes for advanced melanoma; however, there remains a need for novel approaches to overcome disease progression and treatment resistance.
Jordan Phillipps, George Nassief, Renee Morecroft, Tolulope Adeyelu, Andrew Elliott, Farah Abdulla, Ari Vanderwalde, Soo Park, Omar Butt, Alice Zhou, George Ansstas   +10 more
doaj   +1 more source

Identification of 15 lncRNAs Signature for Predicting Survival Benefit of Advanced Melanoma Patients Treated with Anti-PD-1 Monotherapy

Cells, 2021
The blockade of programmed cell death protein 1 (PD-1) as monotherapy has been widely used in melanoma, but to identify melanoma patients with survival benefit from anti-PD-1 monotherapy is still a big challenge.
Jian-Guo Zhou, Bo Liang, Jian-Guo Liu, Su-Han Jin, Si-Si He, Benjamin Frey, Ning Gu, Rainer Fietkau, Markus Hecht, Hu Ma, Udo S. Gaipl   +10 more
doaj   +1 more source

Advances in Vaccines for Melanoma

Hematology/Oncology Clinics of North America
Personalized neoantigen vaccines have achieved major advancements in recent years, with studies in melanoma leading progress in the field. Early clinical trials have demonstrated their feasibility, safety, immunogenicity, and potential efficacy. Advances in sequencing technologies and neoantigen prediction algorithms have substantively improved the ...
Cui, Can, Ott, Patrick A., Wu, Catherine J.   +2 more
openaire   +2 more sources